Repare Therapeutics is a precision medicine oncology company focused on the development of synthetic lethality (SL)-based therapies to patients with cancer. Using Co.'s SNIPRx platform, Co. is developing its pipeline of SL product candidates, including its primary product candidate, RP-3500, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ATM gene (ataxia telangiectasia mutated kinase). Co. is also developing an inhibitor of polymerase theta, which is SL with multiple gene deficiencies found in tumors. We show 18 historical shares outstanding datapoints in our RPTX shares outstanding history coverage, used to compute RPTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing RPTX market cap history over the course of time is important for investors
interested in comparing RPTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of RPTX versus a peer is one thing; comparing
RPTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like RPTX can fluctuate over the course of history.
With this page we aim to empower investors researching RPTX by allowing them to research the RPTX market cap history. |
Free RPTX Email Alerts:
Video: The Importance of Market Cap
